KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Alnylam Pharmaceuticals (ALNY) over the last 13 years, with Q3 2025 value amounting to $55.8 million.

  • Alnylam Pharmaceuticals' Other Non-Current Assets fell 2806.44% to $55.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.8 million, marking a year-over-year decrease of 2806.44%. This contributed to the annual value of $65.3 million for FY2024, which is 550.55% up from last year.
  • Alnylam Pharmaceuticals' Other Non-Current Assets amounted to $55.8 million in Q3 2025, which was down 2806.44% from $57.2 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Other Non-Current Assets high stood at $92.7 million for Q2 2023, and its period low was $34.6 million during Q2 2021.
  • Moreover, its 5-year median value for Other Non-Current Assets was $65.3 million (2024), whereas its average is $63.7 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first surged by 12423.29% in 2021, then plummeted by 2806.44% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $60.2 million in 2021, then increased by 9.78% to $66.1 million in 2022, then dropped by 6.34% to $61.9 million in 2023, then grew by 5.51% to $65.3 million in 2024, then dropped by 14.51% to $55.8 million in 2025.
  • Its Other Non-Current Assets stands at $55.8 million for Q3 2025, versus $57.2 million for Q2 2025 and $73.8 million for Q1 2025.